AZT myopathy and HIV-1 polymyositis: One disease or two?

Kimberley Walsh, Kathy Kaye, Bart M Demaerschalk, Sarah Stewart, Jeff Crukley, Robert Hammond

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: This paper discusses the association between inflammatory and mitochondrial pathologies in patients with HIV-1/AIDS treated with zidovudine (AZT). Methods: We present the clinical and pathological details of a 52-year-old HIV-1 positive male who presented with progressive muscle weakness. We also review the current literature and address the debated pathogenesis of the inflammatory pathology. Results: Muscle biopsy revealed evidence of both HIV-1 polymyositis and AZT myopathy. Six months after initiation of corticosteroid therapy and discontinuation of AZT, the patient's symptoms had greatly improved. The biopsy was repeated to show that both pathologies had resolved. Conclusions: The perceived overlap in the pathological spectra of HIV-1 polymyositis and AZT myopathy has produced some debate on causation and treatment. Unfortunately, there have been very few reports where a repeat biopsy following a drug washout period confirmed resolution of the pathology. Furthermore, affected patients have not been treated in a uniform fashion. Whether this represents one disease or two remains uncertain. The clinical relevance of this issue lies in the potential for harm from the unnecessary use of corticosteroids. This question may be best addressed by a randomized clinical trial.

Original languageEnglish (US)
Pages (from-to)390-393
Number of pages4
JournalCanadian Journal of Neurological Sciences
Volume29
Issue number4
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Polymyositis
Muscular Diseases
HIV-1
Pathology
Biopsy
Adrenal Cortex Hormones
Zidovudine
Muscle Weakness
Causality
Acquired Immunodeficiency Syndrome
Randomized Controlled Trials
Muscles
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Walsh, K., Kaye, K., Demaerschalk, B. M., Stewart, S., Crukley, J., & Hammond, R. (2002). AZT myopathy and HIV-1 polymyositis: One disease or two? Canadian Journal of Neurological Sciences, 29(4), 390-393.

AZT myopathy and HIV-1 polymyositis : One disease or two? / Walsh, Kimberley; Kaye, Kathy; Demaerschalk, Bart M; Stewart, Sarah; Crukley, Jeff; Hammond, Robert.

In: Canadian Journal of Neurological Sciences, Vol. 29, No. 4, 11.2002, p. 390-393.

Research output: Contribution to journalArticle

Walsh, K, Kaye, K, Demaerschalk, BM, Stewart, S, Crukley, J & Hammond, R 2002, 'AZT myopathy and HIV-1 polymyositis: One disease or two?', Canadian Journal of Neurological Sciences, vol. 29, no. 4, pp. 390-393.
Walsh K, Kaye K, Demaerschalk BM, Stewart S, Crukley J, Hammond R. AZT myopathy and HIV-1 polymyositis: One disease or two? Canadian Journal of Neurological Sciences. 2002 Nov;29(4):390-393.
Walsh, Kimberley ; Kaye, Kathy ; Demaerschalk, Bart M ; Stewart, Sarah ; Crukley, Jeff ; Hammond, Robert. / AZT myopathy and HIV-1 polymyositis : One disease or two?. In: Canadian Journal of Neurological Sciences. 2002 ; Vol. 29, No. 4. pp. 390-393.
@article{282ae946d2e040c9b5a948f3b2bb47c1,
title = "AZT myopathy and HIV-1 polymyositis: One disease or two?",
abstract = "Purpose: This paper discusses the association between inflammatory and mitochondrial pathologies in patients with HIV-1/AIDS treated with zidovudine (AZT). Methods: We present the clinical and pathological details of a 52-year-old HIV-1 positive male who presented with progressive muscle weakness. We also review the current literature and address the debated pathogenesis of the inflammatory pathology. Results: Muscle biopsy revealed evidence of both HIV-1 polymyositis and AZT myopathy. Six months after initiation of corticosteroid therapy and discontinuation of AZT, the patient's symptoms had greatly improved. The biopsy was repeated to show that both pathologies had resolved. Conclusions: The perceived overlap in the pathological spectra of HIV-1 polymyositis and AZT myopathy has produced some debate on causation and treatment. Unfortunately, there have been very few reports where a repeat biopsy following a drug washout period confirmed resolution of the pathology. Furthermore, affected patients have not been treated in a uniform fashion. Whether this represents one disease or two remains uncertain. The clinical relevance of this issue lies in the potential for harm from the unnecessary use of corticosteroids. This question may be best addressed by a randomized clinical trial.",
author = "Kimberley Walsh and Kathy Kaye and Demaerschalk, {Bart M} and Sarah Stewart and Jeff Crukley and Robert Hammond",
year = "2002",
month = "11",
language = "English (US)",
volume = "29",
pages = "390--393",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "4",

}

TY - JOUR

T1 - AZT myopathy and HIV-1 polymyositis

T2 - One disease or two?

AU - Walsh, Kimberley

AU - Kaye, Kathy

AU - Demaerschalk, Bart M

AU - Stewart, Sarah

AU - Crukley, Jeff

AU - Hammond, Robert

PY - 2002/11

Y1 - 2002/11

N2 - Purpose: This paper discusses the association between inflammatory and mitochondrial pathologies in patients with HIV-1/AIDS treated with zidovudine (AZT). Methods: We present the clinical and pathological details of a 52-year-old HIV-1 positive male who presented with progressive muscle weakness. We also review the current literature and address the debated pathogenesis of the inflammatory pathology. Results: Muscle biopsy revealed evidence of both HIV-1 polymyositis and AZT myopathy. Six months after initiation of corticosteroid therapy and discontinuation of AZT, the patient's symptoms had greatly improved. The biopsy was repeated to show that both pathologies had resolved. Conclusions: The perceived overlap in the pathological spectra of HIV-1 polymyositis and AZT myopathy has produced some debate on causation and treatment. Unfortunately, there have been very few reports where a repeat biopsy following a drug washout period confirmed resolution of the pathology. Furthermore, affected patients have not been treated in a uniform fashion. Whether this represents one disease or two remains uncertain. The clinical relevance of this issue lies in the potential for harm from the unnecessary use of corticosteroids. This question may be best addressed by a randomized clinical trial.

AB - Purpose: This paper discusses the association between inflammatory and mitochondrial pathologies in patients with HIV-1/AIDS treated with zidovudine (AZT). Methods: We present the clinical and pathological details of a 52-year-old HIV-1 positive male who presented with progressive muscle weakness. We also review the current literature and address the debated pathogenesis of the inflammatory pathology. Results: Muscle biopsy revealed evidence of both HIV-1 polymyositis and AZT myopathy. Six months after initiation of corticosteroid therapy and discontinuation of AZT, the patient's symptoms had greatly improved. The biopsy was repeated to show that both pathologies had resolved. Conclusions: The perceived overlap in the pathological spectra of HIV-1 polymyositis and AZT myopathy has produced some debate on causation and treatment. Unfortunately, there have been very few reports where a repeat biopsy following a drug washout period confirmed resolution of the pathology. Furthermore, affected patients have not been treated in a uniform fashion. Whether this represents one disease or two remains uncertain. The clinical relevance of this issue lies in the potential for harm from the unnecessary use of corticosteroids. This question may be best addressed by a randomized clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0036862392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036862392&partnerID=8YFLogxK

M3 - Article

C2 - 12463497

AN - SCOPUS:0036862392

VL - 29

SP - 390

EP - 393

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 4

ER -